{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:27:17Z","timestamp":1793946437348,"version":"4.8.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105434","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:19:43Z","timestamp":1781651983000},"page":"105434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Challenges and recent advances in CAR-T cell therapy for solid tumors"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7466-1428","authenticated-orcid":false,"given":"Zhixun","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxue","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3114-9214","authenticated-orcid":false,"given":"Yongbao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib1","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105434_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell."},{"issue":"10509","key":"10.1016\/j.critrevonc.2026.105434_bib4","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(25)01206-1","article-title":"Oncolytic viruses as anticancer agents: clinical progress and remaining challenges","volume":"406","author":"Appleton","year":"2025","journal-title":"Lancet"},{"issue":"108","key":"10.1016\/j.critrevonc.2026.105434_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ads1328","article-title":"An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses","volume":"10","author":"Aunins","year":"2025","journal-title":"Sci. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105434_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy","volume":"78","author":"Bader","year":"2020","journal-title":"Mol. Cell."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105434_bib7","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"issue":"47","key":"10.1016\/j.critrevonc.2026.105434_bib8","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105434_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105434_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s42255-022-00730-6","article-title":"Extracellular acidosis restricts one-carbon metabolism and preserves T cell stemness","volume":"5","author":"Cheng","year":"2023","journal-title":"Nat. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.32604\/or.2023.042383","article-title":"Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy","volume":"32","author":"Chen","year":"2023","journal-title":"Oncol. Res."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105434_bib13","first-page":"14","article-title":"Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors","author":"Chen","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib14","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jamaoncol.2024.3891","article-title":"Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial","volume":"10","author":"Chen","year":"2024","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","article-title":"Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105434_bib16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105434_bib17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib18","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","article-title":"Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study","volume":"38","author":"Derigs","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105434_bib19","article-title":"Major Adverse Events with Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation","author":"Dimitrov","year":"2025","journal-title":"Ann. Emerg. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"640","key":"10.1016\/j.critrevonc.2026.105434_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105434_bib22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105434_bib24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","article-title":"Metabolic and epigenetic regulation of T-cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat. Metab."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib26","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors","volume":"26","author":"Fuc\u00e0","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105434_bib27","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.2025029532","article-title":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105434_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105434_bib29","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1016\/j.ymthe.2025.05.025","article-title":"Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells","volume":"33","author":"Giudice","year":"2025","journal-title":"Mol. Ther."},{"issue":"6769","key":"10.1016\/j.critrevonc.2026.105434_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/science.adp7603","article-title":"Acidosis orchestrates adaptations of energy metabolism in tumors","volume":"390","author":"Groessl","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105434_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105434_bib32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105434_bib33","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","article-title":"Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells","volume":"31","author":"Haas","year":"2023","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105434_bib34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"issue":"6788","key":"10.1016\/j.critrevonc.2026.105434_bib35","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1126\/science.adv7378","article-title":"Sensitive CAR T cells redefine targetable CD70 expression in solid tumors","volume":"391","author":"Hanina","year":"2026","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib36","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105434_bib37","first-page":"904","article-title":"Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors. Nat","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Cancer"},{"issue":"70","key":"10.1016\/j.critrevonc.2026.105434_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abk1692","article-title":"Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy","volume":"7","author":"Hoch","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105434_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117753","article-title":"Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy","volume":"181","author":"Huang","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress","volume":"17","author":"Huang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105434_bib41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105434_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2024-010083","article-title":"Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study","volume":"13","author":"Inthanachai","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105434_bib44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s43018-025-00909-2","article-title":"Linking macrophage metabolism to function in the tumor microenvironment","volume":"6","author":"Jin","year":"2025","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib45","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105434_bib46","first-page":"22","article-title":"Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors","volume":"11","author":"Johnson","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105434_bib48","article-title":"Linking tumour angiogenesis and tumour immunity","author":"Kabir","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105434_bib49","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"issue":"623","key":"10.1016\/j.critrevonc.2026.105434_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105434_bib51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105434_bib52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","article-title":"Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology","volume":"10","author":"Kembuan","year":"2024","journal-title":"Trends Cancer"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105434_bib53","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-024-03817-z","article-title":"Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells","volume":"74","author":"Khaliulin","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105434_bib55","article-title":"Co-stimulation of CD28\/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness","volume":"32","author":"Khopanlert","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib56","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: An Attractive Target for Antibody-based Immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105434_bib57","article-title":"Microenvironmental regulation of solid tumour resistance to CAR T cell therapy","author":"Lamplugh","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib58","first-page":"43","article-title":"Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer","volume":"1","author":"Lanitis","year":"2013","journal-title":"Immunol. Res."},{"issue":"87","key":"10.1016\/j.critrevonc.2026.105434_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg3868","article-title":"Cellular and molecular waypoints along the path of T cell exhaustion","volume":"8","author":"Lan","year":"2023","journal-title":"Sci. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105434_bib60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105434_bib61","first-page":"13","article-title":"Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis","author":"Lei","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell. Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105434_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwae018","article-title":"Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor","volume":"11","author":"Liao","year":"2024","journal-title":"Natl. Sci. Rev."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105434_bib64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105434_bib65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T Cells that Express a PD-1\/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib66","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","article-title":"A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib67","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105434_bib68","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","author":"Locatelli","year":"2025","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105434_bib69","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105434_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121341","article-title":"IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy","volume":"281","author":"Luo","year":"2022","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105434_bib71","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105434_bib72","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","article-title":"Cancer cell metabolism and antitumour immunity","volume":"24","author":"De Martino","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib73","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105434_bib74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cytogfr.2025.12.007","article-title":"Tightly bound T-cell clusters: A new class of hyper-effector tumor killers","volume":"88","author":"Ma","year":"2026","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.critrevonc.2026.105434_bib75","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"Cell Exhaustion During Chronic Viral Infection and Cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105434_bib76","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105434_bib77","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105434_bib78","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105434_bib79","article-title":"Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors","volume":"2","author":"Muliaditan","year":"2021","journal-title":"Cell. Rep. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib80","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1757360","article-title":"Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model","volume":"9","author":"Murty","year":"2020","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib81","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105434_bib82","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105434_bib83","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41577-022-00796-z","article-title":"TGF\u03b2 control of immune responses in cancer: a holistic immuno-oncology perspective","volume":"23","author":"Nixon","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib84","article-title":"Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells","volume":"5","author":"Obajdin","year":"2024","journal-title":"Cell. Rep. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105434_bib85","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib86","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105434_bib87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jitc-2023-007162","article-title":"Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study","volume":"11","author":"Papa","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib88","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1038\/s41467-024-51337-2","article-title":"CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma","volume":"15","author":"Pascual-Pasto","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105434_bib89","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","article-title":"Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism","volume":"25","author":"Peralta","year":"2024","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105434_bib90","first-page":"e1","article-title":"Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma. Transplant Cell Ther","volume":"29","author":"De Philippis","year":"2023"},{"key":"10.1016\/j.critrevonc.2026.105434_bib91","article-title":"CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors","volume":"12","author":"Qin","year":"2021","journal-title":"Front. Immunol."},{"issue":"10494","key":"10.1016\/j.critrevonc.2026.105434_bib92","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105434_bib93","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1126\/scisignal.aap9777","article-title":"An immunoproteomic approach to characterize the CAR interactome and signalosome","volume":"12","author":"Ramello","year":"2019","journal-title":"Sci. Signal."},{"issue":"6726","key":"10.1016\/j.critrevonc.2026.105434_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4793","article-title":"Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs","volume":"386","author":"Reddy","year":"2024","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib95","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105434_bib96","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"6230","key":"10.1016\/j.critrevonc.2026.105434_bib97","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105434_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106329","article-title":"Locoregional delivery of CAR-T cells in the clinic","volume":"182","author":"Sagnella","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105434_bib99","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/blood.2024026831","article-title":"Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma","volume":"145","author":"Samples","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105434_bib100","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.3389\/fimmu.2018.02593","article-title":"T Cells a Solid Option for Solid Tumors","volume":"9","author":"Schmidts","year":"2018","journal-title":"Front. Immunol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105434_bib101","first-page":"3153","article-title":"Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction","volume":"141","author":"Selli","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105434_bib102","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105434_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu4417","article-title":"Low-dose radiation by radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in localized neuroblastoma","volume":"11","author":"Sodji","year":"2025","journal-title":"Sci. Adv."},{"issue":"8047","key":"10.1016\/j.critrevonc.2026.105434_bib104","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105434_bib105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2026.105434_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104751","article-title":"Revolutionizing immunotherapy: The next frontier in CAR T-cell engineering","volume":"211","author":"Suchiita","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105434_bib107","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105434_bib108","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib109","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105434_bib110","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jconrel.2023.09.005","article-title":"Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy","volume":"362","author":"Tang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105434_bib111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2015.11.001","article-title":"Extracellular matrix structure","volume":"97","author":"Theocharis","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib112","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105434_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2021-003826","article-title":"Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells","volume":"10","author":"Tokatlian","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105434_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105434_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105000","article-title":"Balancing Risks and Benefits of Immune Checkpoint Inhibitors in Patients with Pre-existing Immune-Mediated Inflammatory Diseases: A Comprehensive Review","author":"de Torres","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7952","key":"10.1016\/j.critrevonc.2026.105434_bib116","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105434_bib117","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.3389\/ebm.2026.10938","article-title":"How can we balance risk and benefit of interleukin-18 armored T cell therapies?","volume":"251","author":"Vicenova","year":"2026","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105434_bib118","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105434_bib119","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib120","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/j.apsb.2023.12.004","article-title":"The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105434_bib121","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41590-024-01961-3","article-title":"Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control","volume":"25","author":"Weiss","year":"2024","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105434_bib122","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41417-024-00823-2","article-title":"FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma","volume":"31","author":"Xiao","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105434_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib124","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105434_bib125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1084\/jem.20241851","article-title":"Specific loading of oncolytic VSV on CAR enhances CAR-T cell signaling and antitumor activity","volume":"222","author":"Xing","year":"2025","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105434_bib126","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","article-title":"Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors","volume":"30","author":"Yin","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010047","article-title":"Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105434_bib128","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1021\/acsnano.2c12463","article-title":"Nattokinase-Mediated Regulation of Tumor Physical Microenvironment to Enhance Chemotherapy, Radiotherapy, and CAR-T Therapy of Solid Tumor","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105434_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106036","article-title":"Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies","volume":"175","author":"Zhang","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105434_bib130","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1200\/JCO.2024.42.16_suppl.3514","article-title":"Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105434_bib131","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib132","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41569-024-01103-0","article-title":"Extracellular matrix in vascular homeostasis and disease","volume":"22","author":"Zhang","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105434_bib133","article-title":"Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R\/R Acute Lymphoblastic Leukemia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib134","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/acscentsci.2c00163","article-title":"Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy","volume":"8","author":"Zhao","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.critrevonc.2026.105434_bib135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jitc-2021-003176","article-title":"Switch receptor T3\/28 improves long-term persistence and antitumor efficacy of CAR-T cells","volume":"9","author":"Zhao","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105434_bib136","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41423-024-01228-9","article-title":"Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors","volume":"21","author":"Zheng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105434_bib137","first-page":"1022","article-title":"[Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy]","volume":"44","author":"Zhou","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105434_bib138","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202310078","article-title":"Injectable Supramolecular Hydrogels for In Situ Programming of Car-T Cells toward Solid Tumor Immunotherapy","volume":"36","author":"Zhu","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.critrevonc.2026.105434_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103267","article-title":"Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis","volume":"84","author":"Zhu","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105434_bib140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105434_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106454","article-title":"Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor","volume":"184","author":"Zuo","year":"2022","journal-title":"Pharmacol. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:43:55Z","timestamp":1793943835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":141,"alternative-id":["S1040842826003215"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105434","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and recent advances in CAR-T cell therapy for solid tumors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105434"}}